(The Epoch Times)—Johnson & Johnson (J&J) said on Jan. 8 that it has struck a voluntary deal with the Trump administration to lower drug prices for U.S. patients in exchange for tariff relief.
In a statement, the pharmaceutical and medical technology company said it will participate in the TrumpRx.gov platform to allow Americans to purchase its medicines at “significantly discounted rates” and to provide Medicaid program access at prices comparable to those in other developed nations.
J&J said the agreement meets President Donald Trump’s requests to the pharmaceutical sector and ensures the company’s products are exempt from U.S. tariffs.
“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” J&J chairman and CEO Joaquin Duato said in the statement.
“I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation,” Duato added.
Last December, Trump unveiled deals with nine major pharmaceutical companies to reduce prices for medications related to autoimmune diseases, cancer, diabetes, and other disorders for Americans.
